Summary of Product Characteristics
last updated on the eMC:
17/05/2011
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 17/05/2011 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.8 - Undesirable Effects
|
| Date of revision of text on the SPC: 11-May-2011 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| section 4.8 (undeisrable effect)
addition of aseptic meningitis and optic neuropathy/neuritis
|
|
Updated on 25/03/2011 and displayed until 17/05/2011
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
|
| Date of revision of text on the SPC: 16-Mar-2011 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| Section 4.4 - brought in line with CCDS
- addition of info about use in patients with active or chronic severe peripheral or central nervous system disease due to the risk of neurological aggravation, as well side effects to look out for.
- warning about darkening of urine
- Cefuroxime info added and mutagenic potential.
|
|
Updated on 09/02/2011 and displayed until 25/03/2011
|
Reasons for adding or updating:
|
-
Change to section 4.8 - Undesirable Effects
|
| Date of revision of text on the SPC: 31-Jan-2011 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Section 4.8 - Updated in line with company core data sheet:
Immune system disorders: fever added
Psychiatric disorders: depressed mood added
Eye disorders: clarification of duration of side effect
Gastrointestinal disorder: clarification of GI disturbances
Skin and subcut tissue disorders: flushing added
|
|
Updated on 24/09/2008 and displayed until 09/02/2011
|
Reasons for adding or updating:
|
-
New individual SPC (was previously included in combined SPC)
|
| Date of revision of text on the SPC: |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
| None provided |
|